Molecular Diagnostics for Melanoma pp 83-95

Part of the Methods in Molecular Biology book series (MIMB, volume 1102) | Cite as

Markers for Anti-cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma

  • Michael A. Postow
  • Jianda Yuan
  • Shigehisa Kitano
  • Alexander M. Lesokhin
  • Jedd D. Wolchok

Abstract

Therapeutic strategies that block Cytotoxic T lymphocyte antigen-4 (CTLA-4) enhance antitumor immunity and prolong the lives of patients with metastatic melanoma. However, only a subset of patients benefit, and responses are often delayed due to heterogeneous response kinetics. Ongoing monitoring of the immunologic effects of therapy and correlating these immunologic changes with patient outcomes continue to be important goals to better identify possible mechanisms of clinical activity of these agents. This chapter introduces the major areas of investigation in monitoring patients treated with CTLA-4 blockade and provides specific details of our experience performing selected assays.

Key words

Ipilimumab Tremelimumab CTLA-4 Immunologic response biomarkers Absolute lymphocyte count Inducible costimulator Myeloid-derived suppressor cells NY-ESO-1 antigen 

References

  1. 1.
    Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCrossRefGoogle Scholar
  2. 2.
    Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526PubMedCrossRefGoogle Scholar
  3. 3.
    Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454PubMedCrossRefGoogle Scholar
  4. 4.
    Berman D, Wolchok J, Weber J et al (2009) Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 27(suppl): 15s.3020 (abstr)Google Scholar
  5. 5.
    Ku GY, Yuan J, Page DB et al (2010) Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116: 1767–1775PubMedCrossRefGoogle Scholar
  6. 6.
    Postow M, Yuan J, Panageas K et al (2012) Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg). J Clin Oncol 30(suppl):8575, abstrGoogle Scholar
  7. 7.
    Yang A, Kendle RF, Ginsberg BA et al (2010) CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: correlation with clinical outcomes. J Clin Oncol 28(suppl):15s.2555, abstrGoogle Scholar
  8. 8.
    Hodi FS, Butler M, Oble DA et al (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105: 3005–3010PubMedCrossRefGoogle Scholar
  9. 9.
    Hamid O, Schmidt H, Nissan A et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204PubMedCrossRefGoogle Scholar
  10. 10.
    Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372–8377PubMedCrossRefGoogle Scholar
  11. 11.
    Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043–6053PubMedCrossRefGoogle Scholar
  12. 12.
    Maker AV, Phan GQ, Attia P et al (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12:1005–1016PubMedCrossRefGoogle Scholar
  13. 13.
    Maker AV, Yang JC, Sherry RM et al (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29:455–463PubMedCrossRefGoogle Scholar
  14. 14.
    Comin-Anduix B, Lee Y, Jalil J et al (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 6:22PubMedCrossRefGoogle Scholar
  15. 15.
    Burmeister Y, Lischke T, Dahler AC et al (2008) ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol 180:774–782PubMedGoogle Scholar
  16. 16.
    Liakou CI, Kamat A, Tang DN et al (2008) CTLA-4 blockade increases IFNgamma-producing CD4 + ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105: 14987–14992PubMedCrossRefGoogle Scholar
  17. 17.
    Carthon BC, Wolchok JD, Yuan J et al (2010) Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861–2871PubMedCrossRefGoogle Scholar
  18. 18.
    Wang W, Yu D, Sarnaik AA et al (2012) Biomarkers on melanoma patient T Cells associated with ipilimumab treatment. J Transl Med 10:146PubMedCrossRefGoogle Scholar
  19. 19.
    Jungbluth AA, Chen YT, Stockert E et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856–860PubMedCrossRefGoogle Scholar
  20. 20.
    Yuan J, Adamow M, Ginsberg BA et al (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 108:16723–16728PubMedCrossRefGoogle Scholar
  21. 21.
    Klein O, Ebert LM, Nicholaou T et al (2009) Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 15:2507–2513PubMedCrossRefGoogle Scholar
  22. 22.
    Weide B, Zelba H, Derhovanessian E et al (2012) Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 30:1835–1841PubMedCrossRefGoogle Scholar
  23. 23.
    Filipazzi P, Valenti R, Huber V et al (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546–2553PubMedCrossRefGoogle Scholar
  24. 24.
    Poschke I, Mougiakakos D, Hansson J et al (2010) Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70: 4335–4345PubMedCrossRefGoogle Scholar
  25. 25.
    Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931PubMedCrossRefGoogle Scholar
  26. 26.
    Kitano S, Postow M, Cortez C et al (2012) Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma. J Clin Oncol 30(suppl):2518, abstrGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Michael A. Postow
    • 1
  • Jianda Yuan
    • 1
  • Shigehisa Kitano
    • 1
  • Alexander M. Lesokhin
    • 1
  • Jedd D. Wolchok
    • 1
  1. 1.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations